Werewolf Therapeutics, Inc. HOWL 深 滬
已收盤 08-07 16:00:00 美东时间
0.3971
-0.006
-1.42%
華盛通- 最 高0.426
- 今 開0.4067
- 成交量 39.11万股
- 最 低 0.3971
- 昨 收 0.4028
- 總市值 1929.87万
- 52周最高 2.38
- 市盈率 靜 --
- 換手率 0.80%
- 52周最低 0.27
- 委 比 93.20%
- 總股本 4859.91万
- 歷史最高 23.99
- 量 比 0.45
- 振 幅 7.17%
- 歷史最低 0.27
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Werewolf Therapeutics shares are trading lower after the company reported Q2 financial results. Weakness may have stemmed from cash pressure, reliance on one‑time revenue from Jazz asset sale, and uncertainty around management’s strategic review.
Werewolf Therapeutics shares are trading lower after the company reported Q2 financial results. Weakness may have stemmed from cash pressure, reliance on one‑time revenue from Jazz asset sale, and uncertainty around management’s strategic review.
08-01 03:37
Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.29) by 127.59 percent. This is a 120 percent increase over losses of $(0.40) per share from the same period last year. The company reported $21.000 million in sales thi...
07-31 19:27
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Werewolf Therapeutics reported Q2 2026 results, including a $21M payment from asset transactions, enabling continued development of its INDUKINE and INDUCER platforms. Cash decreased to $22M, with collaboration revenue of $21M and net income of $3.7M. The company plans to update on strategic alternatives and clinical trials in H2 2026.
07-31 11:00
Why e.l.f. Beauty Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expectations with fourth-quarter earnings of 32 cents per share and revenue of $449.29 million, up 35%. Other pre-market gainers include WHLR, ATPC, LIMN, JUNS, ILLR, NCPL, VIDA, WNW, and APLD. The biggest losers are WGRX, MMA, IPW, and CAPS.
05-21 17:21
Werewolf Therapeutics Q1 EPS $(0.28), Inline
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 30 percent increase over losses of $(0.40) per share from the same period last year.
05-08 04:45
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Werewolf Therapeutics Q4 EPS $(0.20) Beats $(0.35) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.35) by 43.18 percent. This is a 56.52 percent increase over losses of $(0.46) per share
03-27 19:02
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics announced a strategic review to maximize shareholder value, exploring options like sale, merger, or partnerships, with Piper Sandler as advisor. Q4 and 2025 financials showed cash of $57.1M, reduced R&D and G&A expenses, and narrowed net loss to $8.4M from $20.4M. Strategic alternatives are under consideration without a set timeline.
03-27 11:00
Werewolf Therapeutics Begins Strategic Alternatives Review Process
Werewolf Therapeutics ( ($HOWL) ) has shared an announcement. On February 24, 2...
02-25 07:22
